Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma

Shi,Xi‑Nan; Li,Hongjian; Yao,Hong; Liu,Xu; Li,Ling; Leung,Kwong‑Sak; Kung,Hsiang‑Fu; Lin,Marie  Chia‑Mi

doi:10.3892/mmr.2015.4310

Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma

Authors:
- Xi‑Nan Shi
- Hongjian Li
- Hong Yao
- Xu Liu
- Ling Li
- Kwong‑Sak Leung
- Hsiang‑Fu Kung
- Marie Chia‑Mi Lin
View Affiliations

Affiliations: Biotechnology Center, Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Department of Computer Science and Engineering, Chinese University of Hong Kong, Hong Kong 999077, P.R. China, The Cancer Biotherapy Institute of Jiangsu, Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China
Published online on: September 10, 2015 https://doi.org/10.3892/mmr.2015.4310
Pages: 6501-6508
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin-dependent kinase 2 (CDK2) has been reported to be overexpressed in human colorectal cancer; it is responsible for the G1‑to‑S‑phase transition in the cell cycle and its deregulation is a hallmark of cancer. The present study was the first to use idock, a free and open‑source protein‑ligand docking software developed by our group, to identify potential CDK2 inhibitors from 4,311 US Food and Drug Administration‑approved small molecular drugs with a re‑purposing strategy. Among the top compounds identified by idock score, nine were selected for further study. Among them, adapalene (ADA; CD271,6‑[3‑(1‑adamantyl)‑4‑methoxyphenyl]‑2‑naphtoic acid) exhibited the highest anti‑proliferative effects in LOVO and DLD1 human colon cancer cell lines. Consistent with the expected properties of CDK2 inhibitors, the present study demonstrated that ADA significantly increased the G1‑phase population and decreased the expression of CDK2, cyclin E and retinoblastoma protein (Rb), as well as the phosphorylation of CDK2 (on Thr‑160) and Rb (on Ser‑795). Furthermore, the anti‑cancer effects of ADA were examined in vivo on xenograft tumors derived from DLD1 human colorectal cancer cells subcutaneously inoculated in BALB/C nude mice. ADA (20 mg/kg orally) exhibited marked anti‑tumor activity, comparable to that of oxaliplatin (40 mg/kg), and dose‑dependently inhibited tumor growth (P<0.05), while combined administration of ADA and oxaliplatin produced the highest therapeutic effect. To the best of our knowledge, the present study was the first to indicate that ADA inhibits CDK2 and is a potential candidate drug for the treatment of human colorectal cancer.

View Figures

View References

1	Morgan DO: Cyclin-depend kinases: engines, clocks, and microprocessors. Ann Rev Cell Dev Biol. 13:261–291. 1997. View Article : Google Scholar
2	Sherr CJ and Roberts JM: CDK inhibitor: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
3	Murray AW: Recycling the cell cycle: Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
4	Carnero A: Targeting the cell cycle for cancer therapy. Br J Cancer. 87:129–133. 2002. View Article : Google Scholar : PubMed/NCBI
5	Webster KR and Kimball D: Novel drugs targeting the cell cycle. Emerging Drugs. 5:45–59. 2000. View Article : Google Scholar
6	Senderowicz AM: Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 17:313–320. 1999. View Article : Google Scholar
7	De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M and Kim SH: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 243:518–526. 1997. View Article : Google Scholar : PubMed/NCBI
8	Glab N, Labidi B, Qin LX, Trehin C, Bergounioux C and Meijer L: Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Lett. 353:207–211. 1994. View Article : Google Scholar : PubMed/NCBI
9	Li H, Leung KS and Wong MH: idock: A multithreaded virtual screening tool for flexible ligand docking. Proceedings of the 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB); San Diego. pp. 77–84. 2012
10	Li H, Leung KS, Ballester PJ and Wong MH: Istar: A web platform for large-scale protein-ligand docking. PLoS One. 9:e856782014. View Article : Google Scholar : PubMed/NCBI
11	Millikan LE: Adapalene: An update on newer comparative studies between the various retinoids. Int J Dermatol. 39:784–788. 2000. View Article : Google Scholar : PubMed/NCBI
12	Ocker M, Herold C, Ganslmayer M, Hahn EG and Schuppan D: The synthetic retinoid adapalene inhibites proliferation and induces apoptosis in colorectal cancer cells in vitro. Int J Cancer. 107:453–459. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ocker M, Herold C, Ganslmayer M, Zopf S, Hahn EG and Schuppan D: Potentiated anticancer effects on hepatoma cells by the retinoid adapalene. Cancer Lett. 208:51–58. 2004. View Article : Google Scholar : PubMed/NCBI
14	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The protein data bank. Nucleic Acids Res. 28:235–242. 2000. View Article : Google Scholar
15	Irwin JJ and Shoichet BK: ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model. 45:177–182. 2005. View Article : Google Scholar : PubMed/NCBI
16	Irwin JJ, Sterling T, Mysinger MM, Bolstad ES and Coleman RG: ZINC: A free tool to discover chemistry for biology. J Chem Inf Model. 52:1757–1768. 2012. View Article : Google Scholar : PubMed/NCBI
17	Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS and Olson AJ: AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 30:2785–2791. 2009. View Article : Google Scholar : PubMed/NCBI
18	Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 7:129–141. 2005. View Article : Google Scholar : PubMed/NCBI
19	Abrahart EN: Dyes and their intermediates. Pergamon Press; Oxford: 1968
20	Bernard BA: Adapalene, a newchemical entity with retinoid activity. Skin Pharmacol. 6(Suppl 1): S61–S69. 1993. View Article : Google Scholar
21	Fremont-Smith M, Meigs JV, Graham RM and Gilbert HH: Cancer of endometrium and prolonged estrogen therapy. J Am Med Assoc. 131:805–808. 1946. View Article : Google Scholar : PubMed/NCBI
22	Overbeek GA and de Visser: A comparison of the myotrophic and androgenic activities of the phenylpropionates and decanoates of testosterone and nandrolone. Acta Endocrinol (Copenh). 38:285–292. 1961.
23	Bartoszyk GD, Hegenbart R and Ziegler H: EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol. 322:147–153. 1997. View Article : Google Scholar : PubMed/NCBI
24	Tasaka K and Akagi M: Anti-allergic properties of a new histamine antagonist, 4-(p-chlorobenzyl)-2-[N-methyl-perhy-droazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride (azelastine). Arzneimittelforschung. 29:488–493. 1079.
25	Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S and Ohno Y: Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 572:160–170. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P and Eerdekens M: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 27:6–14. 2007. View Article : Google Scholar : PubMed/NCBI
27	Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Mr Hallsworth A , Robinson SP, Petrie K, Sparidans RW, et al: Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma. Clin Cancer Res. pii: clincanres.0313.2015 [Epub ahead of print]. 2015. View Article : Google Scholar : PubMed/NCBI
28	Li H, Leung KS, Nakane T and Wong MH: iview: An interactive WebGL visualizer for protein-ligand complex. BMC Bioinformatics. 15:562014. View Article : Google Scholar : PubMed/NCBI
29	Stierand K and Rarey M: PoseView-molecular interaction patterns at a glance. J Cheminform. 2(Suppl 1): P502010. View Article : Google Scholar
30	Pines J: Four-dimensional control of the cell cycle. Nat Cell Biol. 1:E73–E79. 1999. View Article : Google Scholar : PubMed/NCBI
31	Furuno N, den Elzen N and Pines J: Human cyclin A is required for mitosis until mid prophase. J Cell Biol. 147:295–306. 1999. View Article : Google Scholar : PubMed/NCBI
32	Juan G and Cordon-Cardo C: Intranuclear compartmentalization of cyclin E during the cell cycle: Disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res. 61:1220–1226. 2001.PubMed/NCBI
33	Ohi R and Gould KL: Regulating the onset of mitosis. Curr Opin Cell Biol. 11:267–273. 1999. View Article : Google Scholar : PubMed/NCBI
34	Reed SI: Control of the G1/S transition. Cancer Surv. 29:7–23. 1997.PubMed/NCBI
35	Cobrinik D: Pocket proteins and cell cycle control. Oncogene. 24:2796–2809. 2005. View Article : Google Scholar : PubMed/NCBI
36	Meraldi P, Lukas J, Fry AM, Bartek J and Nigg EA: Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol. 1:88–93. 1999. View Article : Google Scholar : PubMed/NCBI
37	Agouron: 3,5-Disubstituted indazole compounds. Pharmaceutical compositions, or method for mediating or inhibiting cell proliferation. US 0142345. 2006
38	Astex: Preparation of 3,4-disubstituted 1 h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators. WO 012256. 2005
39	Astex: Preparation of 3,4-disubstituted pyrazoles as inhibitors of cyclin dependent kinases (CDK), Aurora A kinase or glycogen synthase kinase 3 (GSK3). WO 003440. 2006
40	Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, et al: Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol. 21:884–894. 2010. View Article : Google Scholar :
41	Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Geh C, Green CP, Johannsen M, Walker M and Weir HM: Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 18:6486–6489. 2008. View Article : Google Scholar : PubMed/NCBI
42	Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, et al: The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett. 18:6369–6373. 2008. View Article : Google Scholar : PubMed/NCBI
43	Gucký T, Jorda R, Zatloukal M, Bazgier V, Berka K, Řezníčková E, Béres T, Strnad M and Kryštof V: A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors. J Med Chem. 56:6234–6247. 2013. View Article : Google Scholar : PubMed/NCBI
44	Shapiro GI, Bannerji R, Small K, et al: A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies. J Clin Oncol (Meeting Abstracts). 26:35322008.
45	Nemunaitis J, Saltzman M, Rosenberg MA, et al: A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Clin Oncol (Meeting Abstracts). 27:35352009.
46	Trott O and Olson AJ: AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 31:455–461. 2010.
47	Hensby C, Cavey D, Bouclier M, Chatelus A, Algate D, Eustache J and Shroot B: The in vivo and in vitro anti-inflammatory activity of CD271: A new retinoid-like modulator of cell differentiation. Agents Actions. 29:56–58. 1990. View Article : Google Scholar : PubMed/NCBI
48	Tashiro T, Kawada Y, Samurai Y and Kidan Y: Antitumor activity of a new platinum complex, Oxalato(trans-l-1,2-diaminocyclohexane) platinum(II): New experimental data. Bioed Pharmacother. 43:251–260. 1989. View Article : Google Scholar